Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19. Issue 9 (12th August 2021)

• Record Type: Journal Article
• Authors: Munblit, Daniel; Bobkova, Polina; Spiridonova, Ekaterina; Shikhaleva, Anastasia; Gamirova, Aysylu; Blyuss, Oleg; Nekliudov, Nikita; Bugaeva, Polina; Andreeva, Margarita; DunnGalvin, Audrey; Comberiati, Pasquale; Apfelbacher, Christian; Genuneit, Jon; Avdeev, Sergey; Kapustina, Valentina; Guekht, Alla; Fomin, Victor; Svistunov, Andrey A.; Timashev, Peter; Subbot, Vladislav S.; Royuk, Valery V.; Drake, Thomas M.; Hanson, Sarah Wulf; Merson, Laura; Carson, Gail; Horby, Peter; Sigfrid, Louise; Scott, Janet T.; Semple, Malcolm G.; Warner, John O.; Vos, Theo; Olliaro, Piero; Glybochko, Petr; Butnaru, Denis;
• Other Names: Abdeeva Elina investigator.; Alekseeva Nikol investigator.; Antsiferova Elena investigator.; Artigas Elena investigator.; Bairashevskaia Anastasiia investigator.; Belkina Anna investigator.; Bezrukov Vadim investigator.; Bordyugov Semyon investigator.; Bratukhina Maria investigator.; Chen Jessica investigator.; Deunezhewa Salima investigator.; Elifkhanova Khalisa investigator.; Ezhova Anastasia investigator.; Filippova Yulia investigator.; Frolova Aleksandra investigator.; Ganieva Julia investigator.; Gorina Anastasia investigator.; Kalan Yulia investigator.; Kirillov Bogdan investigator.; Korgunova Mariia investigator.; Krupina Alexandra investigator.; Kuznetsova Anna investigator.; Listovskaia Ekaterina investigator.; Mikheeva Margarita investigator.; Mursalova Aigun investigator.; Ogandzhanova Marina investigator.; Parr Callum investigator.; Rumyantsev Mikhail investigator.; Smirnov Denis investigator.; Shishkina Nataliya investigator.; El‐Taravi Yasmin investigator.; Varaksina Maria investigator.; Vodianova Maria investigator.; Zezyulina Anna investigator.;
• Is Part Of: Clinical & experimental allergy. Volume 51:Issue 9(2021)
• Page Start: 1107
• Page End: 1120
• Publication Date: 2021-08-12
• Subjects: asthma -- COVID‐19 -- long COVID -- PASC -- postacute sequelae SARS‐CoV‐2 infection -- post‐COVID Condition -- post‐COVID Syndrome -- risk factors; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.13997
• Languages: English
• ISSNs: 0954-7894

Abstract

Abstract: Background: The long‐term sequalae of COVID‐19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID‐19 and assessed potential risk factors. Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long‐term Follow‐up Study questionnaire. Results: 2, 649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post‐discharge. COVID‐19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1, 353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions: Almost half of adults admitted to hospital due to COVID‐19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms. Abstract : Word cloud showing persistent symptoms 6–8 months since hospital discharge in people previously hospitalised with COVID‐19.